Drugs / ISM8207
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06445517 | Apr 2024 → Nov 2026 expected | cancer, lymphoma | InSilico Medicine | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISM8207 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06445517 ↗ |
| Route | Oral | “Mode of Administration: Oral” NCT06445517 ↗ |